A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

Healthy Clinical Trial

Official title:

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04451408
• Other study ID #: 17755
• Secondary ID: J1G-MC-LAKB
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: July 7, 2020
• Est. completion date: October 15, 2024

Study information

• Verified date: May 2024
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. The study will be conducted in two parts. The part A includes participants with AD and part B includes healthy participants. Participation could last up to about 61 weeks and may include up to 31 visits to the study center.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 224
• Est. completion date: October 15, 2024
• Est. primary completion date: August 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

(Part A)

• Gradual and progressive changes in memory function reported by participants or their partners for greater than or equal to (=) 6 months at screening, and a clinical diagnosis of mild cognitive impairment due to AD, or AD dementia, as determined by the investigator or based upon medical history

• Mini-Mental State Examination score =16

• Have clinical laboratory test results within normal reference range or results with acceptable deviations that are judged to be not clinically significant by the investigator

• Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to study visits or be available through telephone at designated times

(Part B)

• overtly healthy males or females

• have a body mass index of 18.0 to 32.0 kg/m2, inclusive

• To qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.

Exclusion Criteria:

(Part A)

• Have history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency

• Contraindication to positron emission tomography (PET)

• Have a history or presence of serious or unstable illnesses including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrine, psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than (<)24 months

• Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing

• Have had significant medical history of dizziness, syncope, or vasovagal attacks within the past 3 years

• Contraindication to magnetic resonance imaging (MRI), including claustrophobia that cannot be managed with low-dose sedatives or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker

(Part B)

• have a family history of early onset AD (AD diagnosed prior to 65 years of age)

• have used or intend to use over-the-counter or prescription medication including herbal medications within 14 days prior to dosing.

• have a history or presence of significant psychiatric disorders

• have an abnormal blood pressure and/or pulse rate as determined by the investigator, or a pre-existing history of hypertension

• any clinically significant ECG or brain MRI abnormalities

Related Conditions & MeSH terms

• Alzheimer Disease
• Healthy

Intervention

Drug:
• LY3372993
Administered IV or SC.
• Placebo
Administered IV or SC.

Locations

Country	Name	City	State
Japan	The University of Tokyo Hospital	Bunkyo-ku	Tokyo
Japan	Clinical Research Hospital Tokyo	Shinjuku-ku	Tokyo
Japan	Oita University Hospital	Yufu	Oita
United States	Altasciences Clinical Los Angeles, Inc	Cypress	California
United States	Covance Dallas	Dallas	Texas
United States	Accel Research Sites- Clinical Research Unit	DeLand	Florida
United States	MD Clinical	Hallandale Beach	Florida
United States	Collaborative Neuroscience Research, LLC	Long Beach	California
United States	IMIC, Inc.	Miami	Florida
United States	Ppd Development	Orlando	Florida
United States	Progressive Medical Research	Port Orange	Florida
United States	Charter Research	The Villages	Florida
United States	Synexus Clinical Research US, Inc.	The Villages	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module	Baseline through Week 61 (part A) and Week 13 (Part B)
Secondary	Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3372993	PK: Cmax of LY3372993	Day 1 Predose through Week 61 (part A) and Week 13 (Part B)
Secondary	PK: Area Under the Concentration Versus Time Curve (AUC) of LY3372993	PK: AUC of LY3372993	Day 1 Predose through Week 61 (part A) and Week 13 (Part B)
Secondary	Pharmacodynamics (PD): Change from Baseline in Cerebral Amyloid Plaque Level (Part A only)	PD: Cerebral amyloid plaque level measured using florbetapir positron emission tomography	Baseline and Week 61 (part A)

External Links

•   A Study of LY3372993 in Participants With Alzheimer's Disease (AD)